Quel est le prix pour PharmaTher Holdings Ltd. (PHRM)

Le prix pour PharmaTher Holdings Ltd. (PHRM) est $0.04403621

Quelle est la capitalisation boursière pour PharmaTher Holdings Ltd. (PHRM)

La capitalisation boursière pour PharmaTher Holdings Ltd. (PHRM) est $4.01M

PharmaTher Holdings Ltd. (PHRM) Prix et Capitalisation Boursière

PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.

Prix pour PHRM	L’actif B	La capitalisation boursière de B	Résultats
$59,895.83 $4.01M	NVDA	$5.452T	+136,014,846.35%
$49,328.69 $4.01M	AAPL	$4.490T	+112,018,364.55%
$45,729.44 $4.01M	GOOG	$4.162T	+103,844,966.51%
$40,389.39 $4.01M	MSFT	$3.676T	+91,718,471.34%
$31,124.64 $4.01M	AMZN	$2.833T	+70,679,556.88%

Prix pour PHRM

L’actif B

La capitalisation boursière de B

Résultats

$59,895.83 $4.01M